Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Cirrhosis
  Free Subscription

Articles published in
N Engl J Med
    September 2025
  1. NOUREDDIN M, Shringarpure R, Yale K
    Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. Reply.
    N Engl J Med. 2025;393:10.
    >> Share

  2. YU L
    Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
    N Engl J Med. 2025;393:10.
    >> Share

    June 2025
  3. GARCIA-TSAO G
    Redefining End Points in MASH Cirrhosis.
    N Engl J Med. 2025;392:2475-2477.
    >> Share

    May 2025
  4. NOUREDDIN M, Rinella ME, Chalasani NP, Neff GW, et al
    Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
    N Engl J Med. 2025 May 9. doi: 10.1056/NEJMoa2502242.
    >> Share

    April 2025
  5. SANYAL AJ, Newsome PN, Kliers I, Ostergaard LH, et al
    Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2025 Apr 30. doi: 10.1056/NEJMoa2413258.
    >> Share

    October 2024
  6. MEI Z, Pu J, Shao Z
    Two Trials of Therapeutics for MASH with Liver Fibrosis.
    N Engl J Med. 2024;391:1461-1462.
    >> Share

  7. POLYZOS SA
    Two Trials of Therapeutics for MASH with Liver Fibrosis.
    N Engl J Med. 2024;391:1461.
    >> Share

    July 2024
  8. SANYAL AJ, Bedossa P, Fraessdorf M, Neff GW, et al
    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
    N Engl J Med. 2024;391:311-319.
    >> Share

    June 2024
  9. LOOMBA R, Hartman ML, Lawitz EJ, Vuppalanchi R, et al
    Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    N Engl J Med. 2024 Jun 8. doi: 10.1056/NEJMoa2401943.
    >> Share

    May 2024
  10. KOWDLEY KV, Levy C, Jones D
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1935-1936.
    >> Share

  11. HIRSCHFIELD GM, Kremer AE, Levy C
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1934-1935.
    >> Share

  12. IJICHI H
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1934.
    >> Share

  13. AREVALO-CANAS C, Arevalo-Serrano J
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1933-1934.
    >> Share

  14. HARRISON SA, Taub R
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
    N Engl J Med. 2024;390:1632-1633.
    >> Share

  15. SABET A
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:1632.
    >> Share

    February 2024
  16. SCHNABL B
    PPAR Agonists in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:855-858.
    >> Share

  17. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
    A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:783-794.
    >> Share

  18. ASSIS DN
    Advancing Second-Line Treatment for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:853-854.
    >> Share

  19. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    >> Share

    November 2023
  20. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    >> Share

  21. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016